Syndax Pharmaceuticals stock tumbles on failed IPF trial
Syndax Pharmaceuticals (SNDX) shares dropped 15% after its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The trial did not show a significant decline in forced vital capacity (FVC). The company will not pursue further IPF development but continues trials for chronic graft-versus-host disease (cGVHD) and other indications.
How this was made
The 30-second read
Why it matters
The negative result likely triggers short‑term price decline but the company retains a pipeline with cGVHD approval and other trials.
Market read
First‑report trial failure for a biotech; material for traders with immediate sell signal.
What to watch
The company continues development in other indications and has an FDA‑approved indication, which could cushion long‑term valuation.
Background
Syndax (NASDAQ:SNDX) is a clinical‑stage biotech focused on epigenetic therapies. The failed IPF trial is the first major readout for axatilimab in this disease.
Ticker impact
Syndax announced its Phase 2 axatilimab trial in IPF failed to meet the primary endpoint, causing a 15% after‑hours share drop.
downward pressure as investors price in the negative trial outcome
Clinical‑trial miss is material for a biotech; the stock fell 15% on the news, indicating strong market reaction.
Market effects
May weigh on other IPF‑focused biotech stocks and raise caution on early‑stage pulmonary‑fibrosis programs.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If axatilimab shows strong safety, investors might view the setback as a temporary hurdle and hold for future cGVHD data.
Key entities
- companySyndax Pharmaceuticals
Biotech developer of axatilimab.
